Q-omics provides the consensus-scored TAS2R2P profile across patient tissues and cancer cell-line models. TAS2R2P expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TAS2R2P is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, TAS2R2P RNA expression shows 14,083 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, KIRC, and THYM as cancer lineages where TAS2R2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAS2R2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAS2R2P survival associations across molecular data types. TAS2R2P RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAS2R2P RNA expression–survival associations across cancer types. High TAS2R2P expression shows unfavorable associations in LIHC, COAD, ACC, LGG and READ, but favorable associations in MESO. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TAS2R2P RNA expression.
This table summarizes TAS2R2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TAS2R2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAS2R2P shows lower tumor expression in KIRC and KICH and higher tumor expression in LUAD, HNSC, LUSC and BLCA. The KIRC box plot shows higher TAS2R2P RNA expression in normal versus tumor tissue (log2 FC = −1.059, t-test p < 0.001).
This table shows molecular features associated with TAS2R2P in patient tissues and cancer cell lines. In patient samples, TAS2R2P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
